121 related articles for article (PubMed ID: 22076940)
1. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.
Dakappagari N; Ho SN; Gascoyne RD; Ranuio J; Weng AP; Tangri S
Cytometry B Clin Cytom; 2012 Mar; 82(2):112-9. PubMed ID: 22076940
[TBL] [Abstract][Full Text] [Related]
2. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
Miles RR; Cairo MS; Satwani P; Zwick DL; Lones MA; Sposto R; Abromovitch M; Tripp S; Angiolillo AL; Roman E; Davenport V; Perkins SL
Br J Haematol; 2007 Aug; 138(4):506-12. PubMed ID: 17659054
[TBL] [Abstract][Full Text] [Related]
4. The use of galiximab in non-Hodgkin lymphoma.
Vinjamaram S; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma; 2008 Oct; 8(5):277-82. PubMed ID: 18854281
[TBL] [Abstract][Full Text] [Related]
5. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma.
Laane E; Tani E; Björklund E; Elmberger G; Everaus H; Skoog L; Porwit-MacDonald A
Cytometry B Clin Cytom; 2005 Mar; 64(1):34-42. PubMed ID: 15669024
[TBL] [Abstract][Full Text] [Related]
7. Fas ligand expression in nodal non-Hodgkin's lymphoma.
Müllauer L; Mosberger I; Chott A
Mod Pathol; 1998 Apr; 11(4):369-75. PubMed ID: 9578088
[TBL] [Abstract][Full Text] [Related]
8. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
9. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis and classification of non-Hodgkin lymphomas.
Barrena S; Almeida J; Del Carmen García-Macias M; López A; Rasillo A; Sayagués JM; Rivas RA; Gutiérrez ML; Ciudad J; Flores T; Balanzategui A; Caballero MD; Orfao A
Histopathology; 2011 May; 58(6):906-18. PubMed ID: 21438908
[TBL] [Abstract][Full Text] [Related]
11. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
[TBL] [Abstract][Full Text] [Related]
12. Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.
Jin MK; Hoster E; Dreyling M; Unterhalt M; Hiddemann W; Klapper W
Histopathology; 2011 Mar; 58(4):586-92. PubMed ID: 21401698
[TBL] [Abstract][Full Text] [Related]
13. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites.
Gervasi F; Lo Verso R; Giambanco C; Cardinale G; Tomaselli C; Pagnucco G
Ann N Y Acad Sci; 2004 Dec; 1028():457-62. PubMed ID: 15650271
[TBL] [Abstract][Full Text] [Related]
15. p27(Kip1) immunostaining for the differential diagnosis of small b-cell neoplasms in trephine bone marrow biopsies.
Kremer M; Dirnhofer S; Nickl A; Hoefler H; Quintanilla-Martínez L; Fend F
Mod Pathol; 2001 Oct; 14(10):1022-9. PubMed ID: 11598173
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL).
Perea G; Altés A; Bellido M; Aventín A; Bordes R; Ayats R; Remacha AF; Espinosa I; Briones J; Sierra J; Nomdedéu JF
Histopathology; 2004 Sep; 45(3):268-74. PubMed ID: 15330805
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
18. The challenge of the microenvironment in B-cell lymphomas.
Coupland SE
Histopathology; 2011 Jan; 58(1):69-80. PubMed ID: 21261684
[TBL] [Abstract][Full Text] [Related]
19. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin's lymphomas: an immunohistochemical and histological study.
Curran RC; Jones EL
J Pathol; 1979 Dec; 129(4):179-90. PubMed ID: 317105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
